2025-04-23 11:26:43 ET
DENVER, Colo., Apr 23, 2025 ( 247marketnews.com )- Low-priced stocks with tight floats and compelling catalysts are fueling trader excitement, offering opportunities for quick gains amid volatile markets. Today, 247marketnews.com highlights five NASDAQ stocks to watch: Jayud Global Logistics (JYD), Siyata Mobile (SYTA), Ensysce Biosciences (ENSC), Silexion Therapeutics (SLXN), and Sonoma Pharmaceuticals (SNOA). From short-covering rebounds to transformative patents and strategic partnerships, these tickers are primed for action.
- Jayud Global Logistics (NASDAQ:JYD) is rebounding after a massive plunge from $8 on April 1-2. The current uptick, likely driven by short covering, presents scalp opportunities for nimble traders. X chatter suggests retail interest in a quick pop, with resistance at $0.50 and support at $0.30. Approach with caution, as volatility reigns.
- Siyata Mobile (NASDAQ:SYTA), with a float of ~4.8 million shares, is trading higher and viewed as significantly undervalued as it advances its $160 million merger with Core Gaming, announced February 26, 2025. The reverse takeover, detailed in its recent SEC Form 20-F, positions SYTA in the $126 billion mobile gaming market, leveraging Core Gaming’s 43 million monthly users and an estimated $80 million in 2024 revenue. Safeguards include a potential special stock dividend ensuring legacy Siyata shareholders retain at least 10% ownership.
- Ensysce Biosciences (NASDAQ: ENSC), a clinical-stage pharma tackling severe pain and opioid abuse, announced a U.S. Patent and Trademark Office Notice of Allowance for its PF9001 OUD treatment, titled “Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof.” With a float of ~5.2 million shares, PF9001 uses TAAP and MPAR technologies to reduce methadone’s cardiac risks, respiratory depression, and overdose potential, offering once-daily dosing.
- Silexion Therapeutics (NASDAQ: SLXN), with a float of ~3 million shares, is climbing after announcing a strategic collaboration with Catalent, to develop its siRNA candidate, SIL204, for KRAS-driven cancers. Catalent will handle formulation and manufacturing at its Limoges, France, facility, optimizing SIL204’s systemic and intratumoral delivery for primary tumors and metastases. Preclinical data shows SIL204’s efficacy against KRAS mutations (G12D, G12V, G12R, Q61H, G13D) in pancreatic cancer models.
- Sonoma Pharmaceuticals (NASDAQ: SNOA) reported the U.K. MHRA registration of its Microcyn HOCl-based acne toner and serum, enabling a launch across 1,200+ stores of a major U.K. pharmacy chain. SNOA’s low float and revenue potenti trader’s favorite.
Today’s watchlist—JYD’s scalp potential, SYTA’s undervalued merger, ENSC’s OUD patent, SLXN’s cancer therapy collaboration, and SNOA’s U.K. expansion—offers diverse low-priced opportunities.
Please click here to view ValueScope’s Core Gaming valuation report.
To review the SEC Form 20-F filing, please go to https://ir.siyata.net/sec-filings/ or www.sec.gov .
Stay Tuned: Don’t Miss Out
To ensure you don’t miss future announcements, we encourage you to sign up for additional information
- Siyata’s Investor Relations Portal: https://ir.siyata.net
- Follow Siyata on X: https://x.com/SiyataMobile
- Click here for Siyata’s investor presentation .
For Investor Relation inquiries or to sign up for updates, please click here .
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata/
The post 5 Low-Priced Stock Moves to Watch—JYD, SYTA, ENSC, SLXN, and SNOA appeared first on 24/7 MarketNews .
For further details see:
5 Low-Priced Stock Moves to Watch—JYD, SYTA, ENSC, SLXN, and SNOA